Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:2.7.10.1 (ERK)
95,504 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Sex differences have been observed in the perinatal sexual differentiation of the neural substrate which regulates territorial marking behavior in the Mongolian gerbil. The present study examines the relative contribution of prenatal and postnatal steroid environment to sexual differentiation in the male and androgenized female using territorial marking behavior as an endpoint. Selective suppression of steroid effects in the pre- and postnatal period was accomplished with the antiandrogen flutamide or the antiestrogen MER-25. Treatment was given prenatally (for 5 days before expected parturition), on the day of birth, and postnatally (to day 10) or prenatally and on the day of birth only. Animals without postnatal antisteroid treatment were intact or were gonadectomized on day 2 and given testosterone propionate (TP) treatment on day 7. (It has previously been shown that day 7 is beyond the period of maximum steroid responsiveness in the male but not in the androgenized female.) MER-25, flutamide, or day-2 ovariectomy had no effect on adult marking behavior responsiveness in females given TP on day 7. All groups marked at normal male frequencies. The presence of flutamide prenatally and on the day of birth in day-2 castrates given TP on day 7 yielded adults with marking responsiveness equivalent to day-7 TP-treated females. In contrast, males given day-7 TP without prenatal and birthday flutamide showed significantly lower marking frequencies, suggesting that the presence of androgen prenatally and on the day of birth rendered day-2 castrates less responsive to TP given on day 7.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Effect of perinatal antisteroid treatment on territorial marking behavior in the mongolian gerbil. 404 29

The transfer of the OCT plasmid from Pseudomonas oleovorans to Pseudomonas putida strain PpGl results in the acquisition of three independent replicons: OCT, factor K, and the MER plasmid. OCT is a nontransmissible plasmid harboring genes that code for the enzymes responsible for the degradation of n-octane. Factor K is a transfer plasmid capable of mobilizing OCT as well as chromosomal genes but incapable of enhancing transfer frequencies of other transmissible plasmids such as CAM, SAL, or RP-1. MER is a self-transmissible plasmid which can confer resistance to high concentrations of mercury salts. While OCT and MER are incompatible with CAM, factor K is compatible with it. Transmissible plasmids such as SAL, CAM, MER, or RP-1 cannot mobilize OCT to any significant extent, and exert strong repression on factor K-mediated transfer of chromosomal genes.
...
PMID:Dissociation and interaction of individual components of a degradative plasmid aggregate in Pseudomonas. 453 Mar 12

The ultrastructural response of the uterine luminal epithelium of the spayed virgin rat was studied as a parameter in screening the effects of antifertility agents which may interfere with implantation. The agents studied were bis-(p-acetoxyphenyl-2-methyl-cyclohexlidene-methane (F-6103), bis-(p-acetoxyphenyl)-2-methyl-4-methylidene-cyclohexylidene-methane (F- 6255), bis-(p-acetoxyphenyl)-1,2,3,4-tetrahydro-1-naphtylidene-methane ( F-6278), trans-(p-2-dimethylaminoethoxyphenyl) -1,2-diphenyl-1-ene (ICI- 46474), 1-(p-(2-diethylaminoethoxy) phenyl) -2-(p-methoxyphenyl-1-phenylethane (MER-25), 3-ethyl-2-methyl-4-pheny; -4-cyclohexenecarboxylic acid, sodium salt (ORF-4563), 1-(2-(p-(3,4,-dihydro-6-methoxy-2-phenyl-1-naphtyl)-phenoxy) ethyl)pyrro lidine, HCI(U-11100A), 2(p-(6-methoxy-2-phenylinden-3-yl) phenoxy)trieth ylamine, HCI (U-11555A) and 2-phenyl-1-p-(beta-pyrrolidinoethoxy) phenyl naphto(2,1-b)-furan (66/179). The substances were tested in spayed rats in spayed rats given progesterone and in spayed rats given progesterone plus estradiol-17 beta. All agents gave an estrogen-like response when given separatly. The response was most marked with the F-compounds and ORF-4563. The F-compounds and ORF-4563 changed the ultrastructure profoundly in progesterone-treated rats while the other compounds had little effect. Progesterone plus estradiol rendered the epithelium suitable for implantation. Each compound except U-1155A inhibited the attachment reaction when given before estradiol.
...
PMID:Attachment reaction of rat uterine luminal epithelium. V. Suppression of the attachment reaction by some antifertility agents. 465 Jun 61

Virgin rats were ovariectomized and tested for induction of maternal behavior by being housed with neonatal young. A postoperative interval of 8 weeks yielded an average latency for the onset of maternal behavior significantly lower than that for intact controls or for virgin females ovariectomized 4 weeks before testing. Replacement of estrogen in the group ovariectomized for 8 weeks or injection of the estrogen antagonist ethamoxytriphetol (MER-25) in the group ovariectomized for 4 weeks changed the average latencies accordingly. Parallel results were obtained for males that were castrated 4 or 8 weeks before testing. It is concluded (i) that maternal behavior is under gonadal control and that this control is normally inhibitory; and (ii) that only after long-term removal of the gonads, resulting presumably in the complete clearance of estrogen and testosterone, is the maternal mediating system finally released from steroid suppression.
...
PMID:Maternal behavior in the rat: facilitation through gonadectomy. 468 88

Reduced cellular immune response is well documented in patients with advanced breast cancer. To investigate immunocompetence at the time of diagnosis, 104 patients with breast cancer staged according to the TNM classification were studied preoperatively and compared with 95 age matched healthy women. Tests of blood mononuclear leukocytes included lymphocyte and monocyte counts, determination of rosette forming T (SER +) and B (MER +) lymphocytes, T lymphocyte subsets defined with monoclonal antibodies (Leu-1, Leu-2a, Leu-3a) and with lectin fractionation (soybean agglutinin, SBA), lymphocyte transformation tests with PHA and ConA and colony formation of T cells in agar (TL-CFC). Two age groups (A: 30-50, B: 51-70 years) and the different tumor stages (I-IV) were analyzed. Patients and controls did not differ in absolute numbers of lymphocytes, T and B cells. In patients of group B the absolute number of monocytes was slightly increased in stages II and III and significantly in stage IV (p less than 0.025). Similarly, the lymphocyte response to PHA was significantly reduced in stage IV group B only (p less than 0.05). ConA induced lymphocyte proliferation and TL-CFC capacity were not different in patients and controls. In the small number of patients and age matched controls, in whom T lymphocyte subsets were determined, the relative numbers of T cells with helper or suppressor phenotype as defined with Leu-3a, Leu-2a, or SBA were similar. In conclusion, in breast cancer, at the time of diagnosis, blood T lymphocyte populations and functions are not altered except in elderly patients with disseminated disease. The monocytosis and reduced PHA responsiveness observed in the latter group may be related phenomena.
...
PMID:[Intact cellular immune response in patients with locally metastasizing breast carcinoma at the time of diagnosis]. 622 73

Thirty-eight patients with small-cell carcinoma were treated with cyclophosphamide, Adriamycin, and VP16-213 + or - MER. Response and survival of the six patients who received radiotherapy prior to entering the study were inferior compared with patients who received chemotherapy alone. Of 32 previously untreated patients, 13 had limited and 19 had extensive disease. Ninety-seven percent of these 32 responded and 63% achieved complete remission (CR). All patients with limited disease had a response and 77% achieved CR. Patients with extensive and limited disease had 91/2 months (range 1-26 months) and 14 months (range 31/2 -42 + months) median survival, respectively. The median survival for all complete responders irrespective of extent of disease was 16 months (range 6 - 42 + months). Three patients with limited disease are disease free more than 34 + months and off all therapy 10 + to 18 + months. Eighteen of 38 patients required antibiotics for fever during neutropenia. Eight patients had MER fevers and nine had serious infections. There were four drug-related deaths. MER therapy did not influence response rate, drug toxicity, or survival, but did add morbidity. This combination chemotherapy alone is an effective treatment for previously untreated small-cell lung cancer patients regardless of extent of disease.
...
PMID:Chemotherapy versus chemoimmunotherapy for small-cell undifferentiated carcinoma of the lung. 625 48

One-hundred-three patients with extensive non-small-cell lung cancer were entered into a prospective, randomized trial to determine the value of MER as an adjuvant to chemotherapy. Patients were stratified according to histology and performance status. All patients received CCNU, methotrexate, and Adriamycin with 48 patients also receiving MER. All patients had a performance status of 2 or less (less than 50% bedridden), 49% had prior radiation therapy, only one patient had prior chemotherapy, and all had extensive disease. Of the patients, 42% had epidermoid cancer, 21% had large cell cancer, 32% had adenocarcinoma, and 4% had mixed adenosquamous or undifferentiated carcinoma. The response rates and response durations of the two treatment regimens were similar. Of the patients, 18% had an objective response; in 4% it was complete. An additional 29% had a stable response. Median duration of response ranged from 21 to 23 weeks. Median survival rates for non-MER and MER treatment groups were 21.5 and 18.6 weeks, respectively. The four complete responders have a survival of 24, 85, 86+, and 129 weeks. MER did not improve response for hematopoietic tolerance, was associated with significant morbidity, and was poorly tolerated. The value of immunotherapy in lung cancer remains to be established.
...
PMID:Combination chemotherapy with and without the methanol-extracted residue of bacillus Calmette-Guerin (MER) in extensive non-small-cell lung cancer: a prospective randomized study for the Piedmont Oncology Association. 626 42

The effect of addition of the nonspecific immunostimulant, MER, to combined treatment with chemotherapy and radiotherapy in small cell carcinoma of the lung was evaluated in a prospective randomized trial involving 102 evaluable patients. Chemotherapy consisted of cyclophosphamide, Adriamycin, vincristine, methotrexate, and CCNU; and radiotherapy was administered to the primary lesion, mediastinum, supraclavicular areas, and whole brain. Of 47 patients administered MER 400 mcg intradermally every six weeks, 12 (26%) attained complete remission with a median survival of 22.9 months. Complete remission was observed in 17 (31%) of 55 patients who received no MER with a median survival of 20.0 months (P greater than 0.05). Survival greater than or equal to 2 years has been observed in five patients who received MER and two patients who did not receive MER. The response rate and duration, survival, and toxicity of the two treatment arms were similar with the exception of cutaneous and occasional systemic reaction to MER. MER as used in this study has not influenced the overall results of a combined modality treatment program for patients with small cell carcinoma of the lung.
...
PMID:Combination chemotherapy-radiotherapy with and without the methanol-extraction residue of Bacillus Calmette-Guerin (MER) in small cell carcinoma of the lung: a prospective randomized trial of the Piedmont Oncology Association. 628 34

Small cell lung cancer requires aggressive combination chemotherapy. The three active agents, doxorubicin (A) 45 mg/m2 i.v. day 1, cyclophosphamide (C) 1.0 mg/m2 i.v. day 1 and VP16-213 (E) 50 mg/m2/day i.v. days 1-5 were given together. The combination (ACE) was given every 21 days without chest irradiation. One hundred and seventy-four patients have been stratified for extent of disease and randomized on three sequential studies testing ACE vs ACE + MER immunotherapy (38 patients), or ACE vs ACE alternating with CCNU, methotrexate, vincristine and procarbazine (109 patients), or ACE vs ACE II (ACE with continuous VP16-213 - 100 mg/m2/day X 5 days - 27 patients - ongoing). The immunotherapy and the alternating non-cross resistant combination have not proven beneficial with respect to response or survival. The ACE combination, regardless of additional treatments, has produced greater than 90% response overall. In limited disease the complete response (CR) frequency is 65%. The median survival for limited disease overall is 14 months and 18 months for patients achieving CR. In extensive disease the CR frequency is 40% with a median survival of 9 months overall and 13 months for patients achieving CR. Response frequency and survival are identical in the first two studies and 20-30% of patients with limited disease are long-term survivors with one late relapse (greater than 3 years). Patients who achieved CR had a significantly longer survival regardless of other factors such as performance status or extent of disease. Prophylactic cranial irradiation was demonstrated to be useful in prevention or delaying CNS metastases in patients who achieved CR. The third generation study of high-dose VP16-213 infusion seeks to increase the CR frequency. ACE chemotherapy without chest irradiation is a highly effective treatment for all patients with small cell lung cancer and compares favorably with all other studies with or without adjuvant radiotherapy.
...
PMID:Doxorubicin, Cyclophosphamide and VP16-213 (ACE) in the treatment of small cell lung cancer. 628 82

The role of antigen concentration on the immunosuppressive effect of adrenocorticotropin (ACTH) was tested in 6-week-old White Rock chickens that were immunized i.v. with 1 ml of heat-treated Salmonella pullorum at packed cell volume concentrations of .06 to .00015%, At 16 and 10 hr before the antigen (Ag) injection, the birds received either 4 IU . 100 g body wt-1 of ACTH i.m., or the gelatin (Gel) vehicle. Total, 2-mercaptoethanol sensitive (2-MES), and 2-mercaptoethanol resistant (2-MER) agglutinin antibody titers were determined. The ACTH significantly suppressed total agglutinin titers with the lower Ag concentrations (.0015 and .00015%) but not with the higher Ag concentrations. The ACTH significantly suppressed 2-MES titers only when Ag concentrations were low but suppressed 2-MER titers regardless of Ag concentration. The results indicated that there may be critical Ag concentrations capable of inducing maximal humoral antibody responses in moderate environments but which allow these responses to be suppressed by environments that stimulate increased pituitary-adrenal activity.
...
PMID:Concentration of Salmonella pullorum antigen and the immunosuppressive effect of adrenocorticotropin in growing chickens. 630 89


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>

---